|
14 Jun 2019 |
ArQule Announces Clinical Proof-of-Concept Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2019 EHA Annual Meeting
|
|
13 Jun 2019 |
Entasis Therapeutics Announces Initial ETX0282 Phase 1 Results
|
|
13 Jun 2019 |
Lumosa to Initiate Phase 2 Human Clinical Trial in the US and Taiwan for Its LT3001, A Novel Drug for the Treatment of Acute Ischemic Stroke
|
|
13 Jun 2019 |
Progenics Pharmaceuticals Doses First Patient in Phase 2 Clinical Study of 1095 Radiotherapy for the Treatment of Metastatic Prostate Cancer
|
|
13 Jun 2019 |
Servier announces European Commission decision to convert conditional approval into standard marketing authorization in patients with aggressive non-Hodgkin B-cell lymphoma for PIXUVRI® (pixantrone)
|
|
13 Jun 2019 |
Terns Pharmaceuticals Initiates a Phase 1 Clinical Trial of TERN-101
|
|
12 Jun 2019 |
Constellation Pharmaceuticals Presentation Highlights Enhanced EZH2 Target Engagement, Leading to Second-Generation EZH2 Inhibitor CPI-0209
|
|
12 Jun 2019 |
Tolero Pharmaceuticals Announces First Patient Dosed with Investigational Agent TP-0903 in Phase 1/2 Study in Patients with Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
|
|
12 Jun 2019 |
OnKure and CU Cancer Center Announce First Patient Enrolled in Clinical Trial of OKI-179, a Potent and Selective HDAC Inhibitor
|
|
12 Jun 2019 |
Pfizer Announces Results from XELJANZ® XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study to Evaluate Methotrexate Withdrawal with a JAK Inhibitor
|
|
12 Jun 2019 |
CymaBay Therapeutics Reports Topline 12-Week Data from an Ongoing Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis
|
|
11 Jun 2019 |
Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients
|
|
10 Jun 2019 |
Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain
|
|
10 Jun 2019 |
Aerpio Initiates Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucoma
|
|
10 Jun 2019 |
Deciphera Pharmaceuticals, Inc. Expands Pipeline with Potential First-in-Class Autophagy Inhibitor to Treat Mutant RAS Cancers
|
|
10 Jun 2019 |
Dr. Reddy's Laboratories Limited Through Its Wholly Owned Subsidiary, Dr. Reddy’s Laboratories SA, Announces Positive Topline Results from Phase 2b Study of PPC-06 in Patients with Moderate to Severe Plaque Psoriasis
|
|
07 Jun 2019 |
Eloxx Pharmaceuticals Presents Positive New Data for Lead Investigational Drug, ELX-02, at the 42nd European Cystic Fibrosis Society Conference (ECFS)
|
|
07 Jun 2019 |
NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough
|
|
07 Jun 2019 |
Boston Biomedical, Inc. Announces the Continuation of the Phase 3 CanStem303C Study of Napabucasin in Patients with Advanced Colorectal Cancer Following Interim Analysis
|
|
07 Jun 2019 |
Astex and Otsuka Announce Results of the Phase 3 ASCERTAIN Study of the Novel Oral Cedazuridine/Decitabine Fixed-Dose Combination (ASTX727) in Patients with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)
|
|
07 Jun 2019 |
US FDA and EMA Accept Applications for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis
|
|
07 Jun 2019 |
Goldfinch Bio Initiates Phase 1 Clinical Trial of GFB-887 for Kidney Disease
|
|
07 Jun 2019 |
vTv Therapeutics Announces Positive Topline Results from Part 1 of the Phase 2 Simplici-T1 Trial in Patients with Type 1 Diabetes
|
|
07 Jun 2019 |
Vivacelle Bio Announces Submission of an IND Application with U.S. FDA for VBI-S, an Injectable Fluid for the Treatment of Patients with Severe Septic Shock
|
|
06 Jun 2019 |
Calquence Phase III ELEVATE-TN trial met primary endpoint at interim analysis in previously-untreated chronic lymphocytic leukaemia
|
